← All trials
NCT07253688
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Dec 31, 2029
- Completion date
- Jul 31, 2030
- First posted
- Nov 28, 2025
- Last posted
- Nov 28, 2025
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- McGill UniversityLead sponsor
- The Peter Doherty InstituteCollaborator
- University of MelbourneCollaborator
- McGill UniversitySponsor investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- McGill UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.